Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer Arnold

Showing results (71-80 of 85) with videos related to

Pageof 9
Sort By:
Clinical & Experimental Ophthalmology|November 20, 2025
Twelve-Month Outcomes of Brolucizumab in Routine Clinical Practice: Fight Retinal Blindness! RegistryTrung M Dang, Alessandro Invernizzi, Vuong Nguyen, et al.
Research in Social & Administrative Pharmacy : RSAP|July 31, 2012
Recruitment of community pharmacies in a randomized trial to generate patient referrals to the tobacco quitlineRobin L Corelli, Alan J Zillich, Carl de Moor, et al.
Ophthalmology. Retina|November 12, 2022
Central Retinal Vein Occlusion 36-Month Outcomes with Anti-VEGF: The Fight Retinal Blindness! RegistryAdrian Hunt, Vuong Nguyen, Sanjeeb Bhandari, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 20, 2005
The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigensRyan D Guest, Robert E Hawkins, Natalia Kirillova, et al.
Journal of Ophthalmology|February 24, 2023
Diabetic Macular Oedema Guidelines: An Australian PerspectiveYew Sen Yuen, Jagjit Singh Gilhotra, Michelle Dalton, et al.
BMJ Open|September 11, 2025
PRevEnting FracturEs in REnal Disease-1 (PREFERRED-1): protocol for a pilot study of a pragmatic, randomised controlled trial of denosumab for the prevention of fragility fractures in haemodialysisKristin K Clemens, Andrea Cowan, Stephanie Dixon, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|November 21, 2002
Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3Neil M Bressler, Jennifer Arnold, Mustapha Benchaboune, et al.
The British Journal of Ophthalmology|March 13, 2021
Twelve-month outcomes of ranibizumab versus aflibercept for macular oedema in branch retinal vein occlusion: data from the FRB! registryAdrian R Hunt, Vuong Nguyen, Catherine P Creuzot-Garcher, et al.
The British Journal of Ophthalmology|October 8, 2025
Minimum set of outcome measures for non-advanced age-related macular degeneration: a Delphi consensus statement by the TRACER (intermediate age-related macular degeneration) study groupMariano Cozzi, Sandrine Zweifel, Konstantinos Balaskas, et al.
Ophthalmology. Retina|April 14, 2024
One-Year Anti-VEGF Therapy Outcomes in Diabetic Macular Edema Based on Treatment Intensity: Data from the Fight Retinal Blindness! RegistryHemal Mehta, Pierre-Henry Gabrielle, Yohei Hashimoto, et al.
Pageof 9

Showing results (71-80 of 85) with videos related to

Sort By:
Pageof 9
Clinical & Experimental Ophthalmology|November 20, 2025
Twelve-Month Outcomes of Brolucizumab in Routine Clinical Practice: Fight Retinal Blindness! RegistryTrung M Dang, Alessandro Invernizzi, Vuong Nguyen, et al.
Research in Social & Administrative Pharmacy : RSAP|July 31, 2012
Recruitment of community pharmacies in a randomized trial to generate patient referrals to the tobacco quitlineRobin L Corelli, Alan J Zillich, Carl de Moor, et al.
Ophthalmology. Retina|November 12, 2022
Central Retinal Vein Occlusion 36-Month Outcomes with Anti-VEGF: The Fight Retinal Blindness! RegistryAdrian Hunt, Vuong Nguyen, Sanjeeb Bhandari, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 20, 2005
The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigensRyan D Guest, Robert E Hawkins, Natalia Kirillova, et al.
Journal of Ophthalmology|February 24, 2023
Diabetic Macular Oedema Guidelines: An Australian PerspectiveYew Sen Yuen, Jagjit Singh Gilhotra, Michelle Dalton, et al.
BMJ Open|September 11, 2025
PRevEnting FracturEs in REnal Disease-1 (PREFERRED-1): protocol for a pilot study of a pragmatic, randomised controlled trial of denosumab for the prevention of fragility fractures in haemodialysisKristin K Clemens, Andrea Cowan, Stephanie Dixon, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|November 21, 2002
Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3Neil M Bressler, Jennifer Arnold, Mustapha Benchaboune, et al.
The British Journal of Ophthalmology|March 13, 2021
Twelve-month outcomes of ranibizumab versus aflibercept for macular oedema in branch retinal vein occlusion: data from the FRB! registryAdrian R Hunt, Vuong Nguyen, Catherine P Creuzot-Garcher, et al.
The British Journal of Ophthalmology|October 8, 2025
Minimum set of outcome measures for non-advanced age-related macular degeneration: a Delphi consensus statement by the TRACER (intermediate age-related macular degeneration) study groupMariano Cozzi, Sandrine Zweifel, Konstantinos Balaskas, et al.
Ophthalmology. Retina|April 14, 2024
One-Year Anti-VEGF Therapy Outcomes in Diabetic Macular Edema Based on Treatment Intensity: Data from the Fight Retinal Blindness! RegistryHemal Mehta, Pierre-Henry Gabrielle, Yohei Hashimoto, et al.
Pageof 9